Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia [0.03%]
伊布替尼联合벤ETOCLUSA治疗初治华氏巨球蛋白血症的II期研究最终报告
Jorge J Castillo,Andrew R Branagan,Alberto Guijosa et al.
Jorge J Castillo et al.
The BTK inhibitor ibrutinib and the BCL-2 antagonist venetoclax are active therapies as single agents in Waldenström macroglobulinemia (WM). In this phase 2 study, we sought to investigate the combination of ibrutinib and venetoclax as a 2...
Exploring Affordable Curative Therapy for Sickle Cell Disease in Africa: A Comprehensive Overview [0.03%]
探索非洲镰状细胞病的经济治疗方案：全面概述
Adetola A Kassim,Alexis A Thompson,Punam Malik
Adetola A Kassim
The practical aspects of developing curative treatments for sickle cell disease (SCD) in Africa, such as gene therapy and hematopoietic stem cell transplantation, involve strengthening healthcare infrastructure, training healthcare professi...
Siana Nkya,Julie Makani,Jonathan M Flanagan
Siana Nkya
Advanced genomic technologies are revolutionizing our ability to understand complex diseases. Large-scale population studies are needed to realize the potential of using individual genetic information to personalize treatments for better pa...
Russell E Ware
Russell E Ware
The Epidemiology of Sickle Cell Disease in Sub-Saharan Africa: Current Knowledge and Gaps to be Filled [0.03%]
非洲撒哈拉以南地区镰状细胞病的流行病学：现有知识及待研究领域
Brigitte Ranque,Leon Tshilolo,Thomas N Williams
Brigitte Ranque
Sickle Cell Disease (SCD) is highly prevalent in sub-Saharan Africa. Epidemiological data remain sparse, but regional screening and research initiatives are expanding. Due to genetic, environmental, and socioeconomic factors, the disease co...
Advancing Sickle Cell Disease Treatment in Sub-Saharan Africa: Challenges and Opportunities for Disease Modifying Therapies [0.03%]
撒哈拉以南非洲镰状细胞病治疗的挑战与疾病修正疗法的机会展望
Yvonne Dei-Adomakoh,Emmanuela E Ambrose,Alexandra Power-Hays
Yvonne Dei-Adomakoh
Sickle cell disease (SCD) is a major individual and public health challenge in sub-Saharan Africa, where over 5 million affected individuals live and where access to disease-modifying treatment is limited. Despite established safety and eff...
Creative and Adaptive Solutions for Early Diagnosis of Sickle Cell Disease in Sub-Saharan Africa [0.03%]
非洲撒哈拉以南地区镰状细胞病早期诊断的创新与适应性解决方案
Luke R Smart,Catherine I Segbefia,Isaac Odame
Luke R Smart
Many of the children with sickle cell disease born in sub-Saharan Africa remain undiagnosed and untreated. Increasing capacity and infrastructure to support diagnostic and screening programs in high income countries have enabled near univer...
Encouraging Outcomes in Pediatric Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Results From the Italian HLH Registry [0.03%]
儿童恶性肿瘤相关性噬血细胞综合征的治疗效果良好：来自意大利噬血细胞性淋巴组织细胞增多症登记处的结果
Francesco Pegoraro,Irene Ferri,Aurora Chinnici et al.
Francesco Pegoraro et al.
Adverse Prognostic Impact of Pretransplant Serum Ferritin and Hepcidin on Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation [0.03%]
allo-HSCT前血清铁蛋白和他尼丁对allo-HSCT后生存结局的不良影响
Michelle Pirotte,Marianne Fillet,Laurence Seidel et al.
Michelle Pirotte et al.
Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma [0.03%]
五年随访：串联CD19 / CD20 CAR T疗法对难治/复发非霍奇金淋巴瘤的持久影响
Fuxin Han,Yadi Zhong,Chuan Tong et al.
Fuxin Han et al.
In this single-arm, single-center, registrational phase 2 trial, tandem CD19/CD20 chimeric antigen receptor (CAR) T cell (TanCAR7) therapy showed promising efficacy and safety in patients with relapsed/refractory non-Hodgkin's lymphoma (r/r...